EGCG (Green Tea Extract)

Disclaimer: The information presented in this section is for educational and informational purposes only. It is not intended as medical advice. No supplement discussed on this site has been proven to prevent, stop, or reverse neurodegenerative disease. While some supplements have been studied for their potential to support aspects of cellular function, any observed effects are generally modest, variable between individuals, and highly context-dependent. Before starting any supplement, consult with a qualified healthcare professional. Appropriate professionals may include a physician, neurologist, pharmacist, nurse practitioner, physician assistant, or registered dietitian. This does not refer to wellness influencers, supplement sellers, health coaches, or practitioners without medical training in pharmacology, neurology, and drug-supplement interactions. Supplements may interact with medications or produce unintended side effects. The inclusion of any supplement on this site does not constitute a recommendation for use. Descriptions of mechanisms or research findings are provided to improve understanding of current scientific investigation, not to guide individual treatment decisions.

Overview

Epigallocatechin gallate (EGCG) is the best-known catechin in green tea and is commonly marketed for antioxidant, anti-inflammatory, and anti-aggregation effects. In neurodegeneration, claims often focus on reducing amyloid or tau pathology, improving cognition, and lowering inflammatory injury.

EGCG is an interesting natural product with good preclinical rationale and limited human evidence. It is one of the more mechanistically attractive polyphenols but is not a clinically established treatment for Alzheimer’s, Parkinson’s, or related disorders.

Proposed Mechanisms

The proposed mechanisms include antioxidant activity, modulation of neuroinflammation, effects on protein aggregation, and support of cellular stress-response pathways. EGCG has also attracted interest because some experimental work suggests it may interact with misfolded protein assemblies in ways relevant to amyloid diseases.

In vivo and mechanistic studies have often shown protective effects in neurologic and inflammatory models. This gives EGCG a stronger preclinical footing than many other popular supplements.

Evidence Summary

Preclinical: The preclinical case is fairly good. Reviews from 2025 and 2026 continue to describe neuroprotective effects across animal and disease models, particularly around oxidative stress, inflammation, and protein aggregation biology.

Translational / RCT / observational: Human evidence remains limited. A 2025 randomized study in APOE-ε4 carriers with subjective cognitive decline looked at EGCG combined with multimodal intervention and suggested some persistent cognitive benefit, but that is not the same as proving EGCG alone prevents or slows neurodegeneration. A 2026 pilot study also explored EGCG in cognitive settings, but the evidence base is still small and preliminary.

Evidence level

Low.

EGCG is more credible than many loosely marketed antioxidant supplements because the mechanism is coherent and the preclinical literature is substantial. But the human neurodegeneration evidence is still too limited to support strong treatment claims.

Limitations

The major limitation is that most of the strongest evidence remains preclinical, while human trials are few, small, and often combine EGCG with other interventions. That makes attribution difficult.

Another limitation is the general translational challenge shared by many polyphenols: formulation, absorption, dosing, and reproducibility across studies.

Safety and Considerations

EGCG is often perceived as automatically safe because it comes from green tea, but concentrated supplement forms are not identical to dietary tea consumption. It also chelates iron, so women and those with anemia should be careful with the dosage.

Sources

Niu L et al. “Dietary (-)-Epigallocatechin Gallate (EGCG): State-of-the-Art Review.” 2026.
Li S et al. “Neurodegenerative diseases and catechins.” Frontiers in Nutrition. 2024.
Forcano L et al. “Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention.” 2025.